Citations

Showing 10 of 108015 citations.

LXVI. Observations on the Management of Tuborrhea. Report of a Series of Twenty-Five Cases
Lillie, Harold I.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | October 3, 2014 | Volume: 29 | Issue: 3 | Pages: 658-665

10.1177/000348942002900311 Get It

XLVII. Angiomas of the Larynx. Report of Three Cases
NEW, G. B., Clark, Candace, NEW, G. B.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | October 3, 2014 | Volume: 28 | Issue: 4 | Pages: 1025-1050

10.1177/000348941902800403 Get It

MALDI-TOF MS for the Diagnosis of Infectious Diseases
Patel, Robin , Patel, Robin

Mayo Clinic

Clinical Chemistry | October 2, 2014 | Volume: 61 | Issue: 1 | Pages: 100-111

10.1373/clinchem.2014.221770 | PMID 25278500 Get It

Abstract BACKGROUND First introduced into clinical microbiology laboratories in Europe, MALDI-TOF MS is being rapidly embraced by laboratories around the globe. Although it has multiple applications, its widespread adoption in clinical microbiology relates to its use as an inexpensive, easy, fast, and accurate method for identification of grown bacteria and fungi based on automated analysis of the mass distribution of bacterial proteins. CONTENT This review provides a historical perspective on this new technology. Modern applications in the clinical microbiology laboratory are reviewed with a focus on the most recent publications in the field. Identification of aerobic and anaerobic bacteria, mycobacteria, and fungi are discussed, as are applications for testing urine and positive blood culture bottles. The strengths and limitations of MALDI-TOF MS applications in clinical microbiology are also addressed. SUMMARY MALDI-TOF MS is a tool for rapid, accurate, and cost-effective identification of cultured bacteria and fungi in clinical microbiology. The technology is automated, high throughput, and applicable to a broad range of common as well as esoteric bacteria and fungi. MALDI-TOF MS is an incontrovertibly beneficial technology for the clinical microbiology laboratory.
Conceptualizing Emergency Department Scenarios
Kaner, Maya, Dror, Shuki , Marmor, Yariv N. , Gadrich, Tamar

Mayo Clinic

Healthcare Administration | October 2, 2014 | Volume: No volume available | Issue: No issue available | Pages: 1351-1368

10.4018/978-1-4666-6339-8.ch073 Get It

To handle problems and trends in emergency department (ED) operations, designers and decision makers often simulate and evaluate various case-specific scenarios before testing them in a real-life environment. However, conceptualizing broad possible scenarios for ED operations prior to simulation operationalization is usually neglected. The authors developed a methodology that integrates design of simulation experiments (DSE) as follows: 1) From a literature survey, they culled generic factors whose varying levels determine possible scenarios; 2) the authors drew up a set of generic interactions among these generic factors; 3) a questionnaire was constructed to serve as an instrument to gather the relevant information from management staff about relevant factors, their levels and interactions for a specific ED. Questionnaire responses support a schematic conceptualization of scenarios that should be simulated for a specific ED. They illustrate the application of the authors' methodology for conceptualization of ED simulation scenarios in two different EDs.
Rapid and Direct Detection of Herpes Simplex Virus in Cerebrospinal Fluid by Use of a Commercial Real-Time PCR Assay
Binnicker, Matthew J. , Espy, Mark J., Irish, Cole L.

Mayo Clinic

Journal of Clinical Microbiology | October 2, 2014 | Volume: 52 | Issue: 12 | Pages: 4361-4362

10.1128/jcm.02623-14 | PMID 25274992 Get It

ABSTRACT Central nervous system infection due to herpes simplex virus (HSV) is a medical emergency and requires rapid diagnosis and initiation of therapy. In this study, we compared a routine real-time PCR assay for HSV types 1 (HSV-1) and 2 (HSV-2) to a recently FDA-approved direct PCR assay (Simplexa HSV-1/2 Direct; Focus Diagnostics, Cypress, CA) using cerebrospinal fluid samples ( n = 100). The Simplexa HSV-1/2 assays demonstrated a combined sensitivity and specificity of 96.2% (50/52) and 97.9% (47/48), respectively. In addition, the Simplexa assay does not require nucleic acid extraction, and the results are available in 60 min.
Different Roles of the Three Loops Forming the Adhesive Interface of Nectin-4 in Measles Virus Binding and Cell Entry, Nectin-4 Homodimerization, and Heterodimerization with Nectin-1
Mateo, Mathieu , Navaratnarajah, Chanakha K. , Willenbring, Robin, Maroun, Justin W. , Iankov, Ianko, Lopez, Marc , Sinn, Patrick L. , Cattaneo, Roberto , Orozco, Robin C. , Willenbring, Robin C, Willenbring, Robin C , Sinn, Patrick L

Mayo Clinic

Journal of Virology | October 2, 2014 | Volume: 88 | Issue: 24 | Pages: 14161-14171

10.1128/jvi.02379-14 | PMID 25275122 Get It

ABSTRACT Many viruses utilize cell adhesion molecules of the immunoglobulin superfamily as receptors. In particular, viruses of different classes exploit nectins. The large DNA viruses, herpes simplex and pseudorabies viruses, use ubiquitous nectins 1 and 2. The negative-strand RNA virus measles virus (MeV) uses tissue-specific nectin-4, and the positive-strand RNA virus poliovirus uses nectin-like 5 (necl-5), also known as poliovirus receptor. These viruses contact the BC, C′C″, and FG loops on the upper tip of their receptor's most membrane-distal domain. This location corresponds to the newly defined canonical adhesive interface of nectins, but how viruses utilize this interface has remained unclear. Here we show that the same key residues in the BC and FG loops of nectin-4 govern binding to the MeV attachment protein hemagglutinin (H) and cell entry, nectin-4 homodimerization, and heterodimerization with nectin-1. On the other hand, residues in the C′C″ loop necessary for homo- and heterotypic interactions are dispensable for MeV-induced fusion and cell entry. Remarkably, the C′C″ loop governs dissociation of the nectin-4 and H ectodomains. We provide formal proof that H can interfere with the formation of stable nectin-1/nectin-4 heterodimers. Finally, while developing an alternative model to study MeV spread, we observed that polarized primary pig airway epithelial sheets cannot be infected. We show that a single amino acid variant in the BC loop of pig nectin-4 fully accounts for restricted MeV entry. Thus, the three loops forming the adhesive interface of nectin-4 have different roles in supporting MeV H association and dissociation and MeV-induced fusion. IMPORTANCE Different viruses utilize nectins as receptors. Nectins are immunoglobulin superfamily glycoproteins that mediate cell-cell adhesion in vertebrate tissues. They interact through an adhesive interface located at the top of their membrane-distal domain. How viruses utilize the three loops forming this interface has remained unclear. We demonstrate that while nectin-nectin interactions require residues in all three loops, the association of nectin-4 with the measles virus hemagglutinin requires only the BC and FG loops. However, we discovered that residues in the C′C″ loop modulate the dissociation of nectin-4 from the viral hemagglutinin. Analogous mechanisms may support cell entry of other viruses that utilize nectins or other cell adhesion molecules of the immunoglobulin superfamily as receptors.
8th International Conference on Oncolytic Virus Therapeutics
Guinn, Barbara‐ann , Braidwood, Lynne, Peng, Kah-Whye , Seymour, Leonard W. , Laengle, Johannes , Parker, Alan L.

Mayo Clinic

Human Gene Therapy | October 2, 2014 | Volume: 25 | Issue: 12 | Pages: 1062-1084

10.1089/hum.2014.118 | PMID 25274574 Get It

Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats
Davis, Myrtle, Bunin, Deborah I., Samuelsson, Steven J., Altera, K. P., Kinders, Robert J. , Ji, Jiuping , Ames, Matthew M. , Buhrow, Sarah A. , Walden, Chad A., Rausch, Linda, Parman, Toufan, Walden, Chad, Reid, Joel M. , Davis, Myrtle, Lawrence, Scott M.

Mayo Clinic

Toxicologic Pathology | October 2, 2014 | Volume: 43 | Issue: 4 | Pages: 519-529

10.1177/0192623314548766 | PMID 25274659 Get It

Batracylin (NSC-320846) is a dual inhibitor of DNA topoisomerases I and II. Batracylin advanced as an anticancer agent to Phase I clinical trials where dose limiting hemorrhagic cystitis (bladder inflammation and bleeding) was observed. To further investigate batracylin’s mechanism of toxicity, studies were conducted in Fischer 344 rats. Once daily oral administration of 16 or 32 mg/kg batracylin to rats for 4 days caused overt toxicity. Abnormal clinical observations and adverse effects on clinical pathology, urinalysis, and histology indicated acute renal damage and urothelial damage and bone marrow dysfunction. Scanning electron microscopy revealed sloughing of the superficial and intermediate urothelial layers. DNA damage was evident in kidney and bone marrow as indicated by histone γ-H2AX immunofluorescence. After a single oral administration of 16 or 32 mg/kg, the majority of batracylin was converted to N-acetylbatracylin (NAB) with a half-life of 4 hr to 11 hr. Mesna (Mesnex™), a drug known to reduce the incidence of hemorrhagic cystitis induced by ifosfamide or cyclophosphamide, was administered to rats prior to batracylin, but did not alleviate batracylin-induced bladder and renal toxicity. These findings suggest that batracylin results in DNA damage-based mechanisms of toxicity and not an acrolein-based mechanism of toxicity as occurs after ifosfamide or cyclophosphamide administration.
Long‐term Dizziness Handicap in Patients with Vestibular Schwannoma: A Multicenter Cross‐sectional Study
Carlson, Matthew L. , Tveiten, Øystein Vesterli , Driscoll, Colin L. W., Neff, Brian A., Shepard, Neil T., Eggers, Scott D.Z. , Staab, Jeffrey P. , Tombers, Nicole M. , Goplen, Frederik Kragerud , Lund‐Johansen, Morten , Link, Michael J. , Driscoll, Colin L., Eggers, Scott D, Staab, Jeffrey P

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 2, 2014 | Volume: 151 | Issue: 6 | Pages: 1028-1037

10.1177/0194599814551132 | PMID 25273693 Get It

Objective (1) To characterize long‐term dizziness following observation, microsurgery, and stereotactic radiosurgery (SRS) for small to medium‐sized vestibular schwannoma (VS) using a validated self‐assessment inventory; and (2) to identify clinical variables associated with long‐term dizziness handicap. Study Design Cross‐sectional observational study. Setting Two independent tertiary academic referral centers: one located in the United States and one in Norway. Subjects and Methods All patients with sporadic VS of less than 3 cm who underwent primary microsurgery, SRS, or observation between 1998 and 2008 were identified. Subjects were surveyed via a postal questionnaire using the Dizziness Handicap Inventory (DHI) and a VS symptom questionnaire. Results The overall survey response rate was 79%. A total of 538 respondents (mean age, 64 years; 56% female) were analyzed, and the mean time interval between treatment and survey was 7.7 years. Pretreatment variables associated with greater dizziness handicap included female sex, older age, larger tumor size, preexisting diagnosis of headache or migraine, and symptoms of dizziness predating treatment. Significant posttreatment features strongly associated with poor long‐term DHI scores included frequency and severity of ongoing headache. On multivariable analysis, treatment modality did not influence long‐term dizziness handicap. Conclusion At a mean of approximately 8 years following treatment, over half of patients with VS reported ongoing dizziness. The authors have identified several baseline features that may help predict the risk of lasting dizziness. Treatment modality does not appear to influence long‐term DHI score. We found a strong association between posttreatment headache and poor dizziness handicap. Future study is needed to further define this relationship.
Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research
O’Bryant, Sid E. , Gupta, Veer Bala , Henriksen, Kim , Jeromin, Andreas, Lista, Simone , Bazenet, Chantal, Soares, Holly , Lovestone, Simon , Hampel, Harald , Montine, Thomas J. , Blennow, Kaj , Foroud, Tatiana, Carrillo, María C. , Graff‐Radford, Neill R. , Laske, Christoph , Breteler, Monique M.B. , Shaw, Leslie M. , Trojanowski, John Q. , Schupf, Nicole , Fagan, Anne M. , Oberoi, Pankaj, Umek, Robert M., Weiner, Michael W. , Grammas, Paula , Posner, Holly, Martins, Ralph N. , groups, STAR-B and BBBIG working, Edwards, Melissa , Rissman, Robert A. , groups, STAR-B and BBBIG working, O'Bryant, Sid

Mayo Clinic

Alzheimer's & Dementia | October 1, 2014 | Volume: 11 | Issue: 5 | Pages: 549-560

10.1016/j.jalz.2014.08.099 | PMID 25282381 Get It

Abstract The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood‐based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross‐validation across cohorts and laboratories.